LANTIDRA

CellTrans Inc.🇺🇸 United States

FDA Page

Effective Date: Jan 13, 2026
Approval ID: 24610d9f-0c5a-4f55-93b3-d456300bfd5d
Products: 1 registered
Version: 3

Regulatory Information

Labeling Type

CELLULAR THERAPY

Status

Approved

Full Title

These highlights do not include all the information needed to use LANTIDRA safely and effectively. See full prescribing information for LANTIDRA. LANTIDRA (donislecel-jujn) Suspension for hepatic portal vein infusion Initial U.S. Approval: 2023

Quick Stats

Total Products1

Labelers1

Label Sections15

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.